Navigation Links
Oncothyreon reports second quarter 2010 financial results
Date:8/5/2010

SEATTLE, Aug. 5 /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ONTY) today reported a net loss of $4.3 million or $0.17 per basic and diluted share for the quarter ended June 30, 2010, compared with a net loss of $6.3 million or $0.30 per basic and diluted share for the comparable period in 2009. Oncothyreon also reported a net loss of $5.1 million or $0.20 per basic and diluted share for the six months ended June 30, 2010, compared with a net loss of $8.8 million or $0.43 per basic and diluted share for the six months ended June 30, 2009. The decrease in net loss for the three and six months ended June 30, 2010 compared to the prior year periods was primarily attributable to a decrease in expense related to the change in fair value of warrant liability partially offset by increases in research and development and general and administrative expenses.

Research and development expenses increased to $2.8 million in the second quarter of 2010 from $2.0 million in the second quarter of 2009, and to $5.3 million for the first six months of 2010 from $2.7 million for the first six months of 2009, reflecting increased development and manufacturing activity for Oncothyreon's product candidates PX-866 and ONT-10. General and administrative expenses increased to
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Oncothyreon announces second quarter 2010 financial results conference call
2. Oncothyreon announces presentations at upcoming investor conferences in June
3. Oncothyreon to present at the Rodman & Renshaw Annual Global Investment Conference
4. Oncothyreon reports full year and fourth quarter 2009 financial results
5. Oncothyreon reports first quarter 2010 financial results
6. Oncothyreon announces temporary suspension of Stimuvax clinical trials by Merck Serono
7. Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement
8. Oncothyreons PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover
9. Oncothyreon reports third quarter 2009 financial results & provides product pipeline update
10. Oncothyreon announces webcast of third quarter 2009 financial results conference call
11. Oncothyreon announces appointment of Douglas E. Williams, Ph.D., to board of directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... ... July 02, 2015 , ... In’Tech ... surgical instruments in Orthopedics, announced today the acquisition of Turner Medical, Inc ... provider of surgical instruments to the Spine Industry. The acquisition of Turner Medical ...
(Date:7/1/2015)... PARIS , July 1, 2015 ... key developer of biotech crops, today announce a ... generations of insect control traits. "Growers ... the realities of advancing insect resistance. We are ... insect control technology with Genective,s capability in developing ...
(Date:7/1/2015)... ... 2015 , ... The next-generation sequencing (NGS) clinical market is poised for huge ... industry. BCC Research reveals in its new report that the market drivers of this ... growing need for better diagnostics as part of a molecular diagnostics trend. , The ...
(Date:7/1/2015)... 1, 2015   Neuraltus Pharmaceuticals, Inc. , a ... groundbreaking drugs to treat neurodegenerative diseases such as ... Robert G. Miller , M.D., Director of the Forbes ... Pacific Medical Center in San Francisco, has been awarded ... million to help fund a Phase 2 clinical ...
Breaking Biology Technology:In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3AgBiome and Genective collaborate to create novel insect-resistant crops 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4
... 2, 2010 Modern Plastics offers SUSTARIN® C ... manufactured by ROCHLING Engineering Plastics. The technology ... sheet and rod are free of centerline or core ... stability for close tolerance parts. A low coefficient of ...
... November 2, 2010 ... ... --> ... first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var r in ...
... Nov. 2, 2010 Repligen Corporation (Nasdaq: ... of fiscal year 2011, ended September 30, 2010.  Total ... total revenue of $5,421,000 for the second quarter of ...  Bioprocessing product revenue for the second quarter was $4,416,000 ...
Cached Biology Technology:Modern Plastics SUSTARIN® C (Acetal) Product Uses Special Manufacturing Technology to Ensure Every Sheet and Rod Are Free of Centerline or Core Porosity 2Elsevier Announces New Partnership With Canadian Cardiovascular Society to Publish the Canadian Journal of Cardiology 2Elsevier Announces New Partnership With Canadian Cardiovascular Society to Publish the Canadian Journal of Cardiology 3Elsevier Announces New Partnership With Canadian Cardiovascular Society to Publish the Canadian Journal of Cardiology 4Elsevier Announces New Partnership With Canadian Cardiovascular Society to Publish the Canadian Journal of Cardiology 5Elsevier Announces New Partnership With Canadian Cardiovascular Society to Publish the Canadian Journal of Cardiology 6Elsevier Announces New Partnership With Canadian Cardiovascular Society to Publish the Canadian Journal of Cardiology 7Elsevier Announces New Partnership With Canadian Cardiovascular Society to Publish the Canadian Journal of Cardiology 8Elsevier Announces New Partnership With Canadian Cardiovascular Society to Publish the Canadian Journal of Cardiology 9Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 2Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 3Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 4Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 5Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 6Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 7
(Date:6/16/2015)... CITY , June 16, 2015 /CNW Telbec/ ... their partnership centralized around the incorporation of handyem,s ... point-of-care diagnostic laboratory, the Mo-POD™. This unprecedented model ... BIO International Conference at the Pennsylvania ... from June 15 th to 18 ...
(Date:6/16/2015)... , June 16, 2015 Fingerprint Cards ... fingerprint sensors in the company,s portfolio from one of its ... planned to mainly take place during the third quarter 2015. ... Asia . Jörgen Lantto, CEO of ...   the   growing interest from smartphone OEMs in integrating ...
(Date:6/15/2015)... 16, 2015 According to a ... Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, ... published by MarketsandMarkets, The Natural Language Processing Market is ... of 18.4% for the forecast period 2015-2020. ... F igures spread   through 155 P ...
Breaking Biology News(10 mins):handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5
... lethal form of brain cancer and the disease that ... efforts, even when attacked simultaneously on several fronts. One ... flexibility, discovered researchers at the Salk Institute for Biological ... glioblastoma cells can shift gears and morph into blood ...
... HOUSTON, Jan. 24, 2011 More than a dozen ... ranging from robot-assisted surgery techniques to improving heart and ... in computational surgery Jan. 26-28. The symposium will be ... Houston. Held at the Methodist Institute ...
... A research effort designed to prevent the introduction of viruses ... helping Chesapeake Bay watermen improve their bottom line by reducing ... market. The findings, published in the journal Diseases of ... virus in diseased and dying crabs likely occurs after the ...
Cached Biology News:Conversion of brain tumor cells into blood vessels thwarts treatment efforts 2Conversion of brain tumor cells into blood vessels thwarts treatment efforts 3Forum to focus on using robotics, imaging and simulation in surgeries 2Forum to focus on using robotics, imaging and simulation in surgeries 3Blue crab research may help Chesapeake Bay watermen improve soft shell harvest 2
Mouse monoclonal [6C3] to JAB1 ( Abpromise for all tested applications). entrezGeneID: 10987 SwissProtID: O15386...
Recombinant Ovine (Sheep) Prolactin, Ultra Pure...
Human LT beta R/TNFRSF3 Phycoerythrin MAb (Clone 71319)...
Human Serpin A3 MAb (Clone 213907)...
Biology Products: